>>
Home > Principal Investigators > Ana Oaknin

PRINCIPAL INVESTIGATORS

ANA OAKNIN

ANA OAKNIN

Current positions

  • Principal Investigator, VHIO´s Gynecological Malignancies Group.
  • Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH).
  • Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH).

Academic Qualifications

  • Degree in Medicine and Surgery, Universidad Complutense de Madrid, 1994.
  • Specialization in Medical Oncology, Hospital Universitario de la Princesa, 1996 – 2000.

Areas of Research

  • DNA repair mechanisms
  • Angiogenesis
  • Immunology

Most relevant scientific publications

  • Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). 2015. Lancet Oncol. 16: 301-311.
  • Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špacek J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. 2015. Lancet Oncol. 16: 87-97.
  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ; ICON7 trial investigators. 2015. Lancet Oncol. 16: 928-936.
  • Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. McMeekin S; Dizon D; Barter J; Scambia G; Manzyuk L; Lisyanskaya A; Oaknin A; Ringuette S; Mukhopadhyay P; Rosenberg J; Vergote I. 2015. Gynecol. Oncol. 138: 18-23.
  • Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. Floquet A; Vergote I; Colombo N; Fiane B; Monk BJ; Reinthaller A; Calvert P; Herzog TJ; Meier W; Kim JW; Del Campo JM; Friedlander M; Pisano C; Isonishi S; Crescenzo RJ; Barrett C; Wang K; Mitrica I; du Bois A. 2015. Gynecol. Oncol.136: 37-42.
  • SEOM guidelines for cervical cancer. Oaknin A; Rubio MJ; Redondo A; De Juan A; Cueva Bañuelos JF; Gil-Martin M; Ortega E; Garcia-Arias A; Gonzalez-Martin A; Bover I. 2015. Clin. Transl. Oncol. 17: 1036-1042.
  • The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. Marth C; du Bois A; Schauer C; du Bois A; Casado A; Vergote I; Del Campo JM; Goudopoulou A; Pujade-Lauraine E; Bruchim I; Colombo N; Pignata S; Ledermann J; Chekerov R; Raza Mirza M; Westermann A; Glasspool R; Taskiran C; Fehr M; Cibula D. 2015. Int. J. Gynecol. Cancer. 25: 1094-1095.
  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8): 799-808
  • Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur. J. Cancer 2014 Sep; 50(14): 2408-16
  • Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, González A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol. Oncol. 2014 Jul; 134(1): 6-9
  • Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, García M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014 Jun; 73(6): 1205-15
  • Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014 May; 32(13): 1302-8
  • Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 2014 Feb; 370(8): 734-43
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Eur. J. Cancer 2014 Mar; 50(4): 862-3
  • Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit. Rev. Oncol. Hematol. 2013 Mar; 85(3): 303-14
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur. J. Cancer 2013 Dec; 49(18): 3831-8

All publications

  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8): 799-808
  • Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur. J. Cancer 2014 Sep; 50(14): 2408-16
  • Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, González A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol. Oncol. 2014 Jul; 134(1): 6-9
  • Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, García M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014 Jun; 73(6): 1205-15
  • Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014 May; 32(13): 1302-8
  • Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 2014 Feb; 370(8): 734-43
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Eur. J. Cancer 2014 Mar; 50(4): 862-3
  • Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit. Rev. Oncol. Hematol. 2013 Mar; 85(3): 303-14
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur. J. Cancer 2013 Dec; 49(18): 3831-8
  • Oaknin A, Diaz de Corcuera I, Rodríguez-Freixinos V, Rivera F, del Campo JM. SEOM guidelines for cervical cancer. Clin Transl Oncol 2012 Jul; 14(7): 516-9
  • Oaknin A, Rodríguez-Freixinos V, Diaz de Corcuera I, Rivera F, del Campo JM. SEOM guidelines for endometrial cancer. Clin Transl Oncol 2012 Jul; 14(7): 512-5
  • Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012 Nov; 70(5): 673-81
  • Oaknin A, Roda D, González-Martin A, Chiva L, García-Donas J, De Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, del Campo JM, Cervantes A, Poveda A. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study. Int. J. Gynecol. Cancer 2011 Aug; 21(6): 1048-55
  • del Campo JM, Muñoz-Couselo E, Diaz de Corcuera I, Oaknin A. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer. Expert Rev Anticancer Ther 2010 Jun; 10(6): 795-805